In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...
While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.
Patients reported clinically meaningful improvements in quality of life and itch. Credit: Hriana / Shutterstock.com. Alumis has announced positive top line data from its Phase III ONWARD1 and ONWARD2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback